- Home
- MNRO vs CCCC Comparison
MNRO vs CCCC Comparison
Compare MNRO & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNRO | CCCC |
|---|---|---|
| Founded | 1957 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.5M | 404.7M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MNRO | CCCC |
|---|---|---|
| Price | $15.71 | $4.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $16.00 | $12.20 |
| AVG Volume (30 Days) | 1.5M | ★ 2.4M |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.69% | N/A |
| EPS Growth | ★ 113.64 | 16.45 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $1,157,176,000.00 | $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.59 | N/A |
| P/E Ratio | $514.00 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $13.51 | $1.40 |
| 52 Week High | $23.91 | $4.60 |
Technical Indicators
Market Signals| Indicator | MNRO | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 61.49 |
| Support Level | $14.90 | $2.10 |
| Resistance Level | $18.56 | $4.60 |
| Average True Range (ATR) | 0.83 | 0.36 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 57.56 | 72.60 |
Price Performance
Historical ComparisonAbout MNRO Monro Inc.
Monro Inc is an operator of retail tire and automotive repair stores in the United States. The company offers replacement tires and tire related services, automotive undercar repair services, and a broad range of routine maintenance services, on passenger cars, light trucks, and vans. It also provides other products and services for brakes; mufflers and exhaust systems; and steering, drive train, suspension, and wheel alignment.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.